China’s Growing Influence in US Drug Market: Harbour BioMed’s Spruce Investment
- Harbour BioMed is transitioning from a traditional contract manufacturer to a research and development partner focused on self-iterating innovation platforms.
- This strategic shift highlights a move towards deeper collaboration with biotechnology companies, extending beyond simple manufacturing services to include joint research and development efforts.
- This approach is exemplified by their collaboration with Spruce Biosciences, as detailed in a recent filing.
Harbour BioMed: A Research and Growth partner
Table of Contents
Harbour BioMed is transitioning from a traditional contract manufacturer to a research and development partner focused on self-iterating innovation platforms.
This strategic shift highlights a move towards deeper collaboration with biotechnology companies, extending beyond simple manufacturing services to include joint research and development efforts. The company aims to be involved in the entire lifecycle of drug development, fostering continuous innovation.
This approach is exemplified by their collaboration with Spruce Biosciences, as detailed in a recent filing.
Spruce biosciences: Development of SPR202
Spruce Biosciences is a biotechnology company focused on developing treatments for rare hormone disorders, including those related to SPR202.
The company licensed SPR202, an early-stage treatment for rare hormone disorders, from Harbour BioMed’s subsidiary, HBM Alpha Therapeutics, for commercialization and development outside of Greater China. This licensing agreement included warrants that Harbour BioMed recently exercised.
As of December 2023, Harbour BioMed held approximately 3.8% of Spruce Biosciences’ total outstanding shares and 3.1% of the fully diluted shares, according to a filing with the Securities and Exchange Commission. SEC Filing – Spruce Biosciences Form 10-Q (Q3 2023)
SPR202: A Treatment for Rare Hormone disorders
SPR202 is an early-stage treatment currently under development for rare hormone disorders.
The drug was licensed by HBM Alpha Therapeutics, a subsidiary of Harbour BioMed, to Spruce Biosciences for development and commercialization outside of Greater China. this licensing agreement demonstrates Harbour BioMed’s strategy of partnering with companies to advance its pipeline of drug candidates globally.
The licensing agreement included financial terms, including the granting of share purchase rights (warrants) to Harbour BioMed, which were subsequently exercised in December 2023.
Details of the Licensing Agreement
The licensing agreement between HBM Alpha Therapeutics and Spruce biosciences granted Spruce exclusive rights to develop and commercialize SPR202 outside of Greater China.
In exchange for these rights, Harbour BioMed received an upfront payment, milestone payments contingent on SPR202’s development progress, and royalties on future sales.The agreement also included warrants, allowing Harbour BioMed to purchase Spruce shares at a predetermined price. spruce Biosciences Q3 2023 Financial Results
Harbour BioMed exercised these warrants in December 2023, resulting in a 3.8% ownership stake in Spruce Biosciences’ total outstanding shares and a 3.1% stake in the fully diluted shares.
Breaking News Check (2026/01/20 23:37:52): As of this date, there have been no significant new developments reported regarding the Harbour BioMed and Spruce Biosciences collaboration or the development of SPR202 beyond the information available in late 2023.Spruce Biosciences continues to be a publicly traded company. Yahoo Finance – Spruce Biosciences (SPRB)